RADINKA JOURNAL OF HEALTH SCIENCE

ISSN: 3025-7751

https://www.rjupublisher.com/ojs/index.php/RJHS

Genetic Methylation Testing: Assessing Important Genes MTHFR, MTRR, MTR, AHCY, and COMT

Md. Tanzimur Rahman TAMIM, Rashed AHMED

Department of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh

Abstract

This study examines the role of genetic methylation testing in assessing key genes involved in the one-carbon cycle: MTHFR, MTR, MTRR, AHCY, and COMT. The methylation process is a fundamental biochemical pathway essential for numerous cellular functions, including DNA synthesis, gene expression, detoxification, and neurotransmitter metabolism. Dysregulation of this pathway, often caused by genetic polymorphisms, can lead to a variety of health problems. This analysis provides an overview of the function of each gene. MTHFR is essential for converting folate to its active form, 5-MTHF. MTR and MTRR are essential for recycling homocysteine to methionine, a process supported by MTRR. AHCY regulates the methylation cycle by cleaving S-adenosylhomocysteine (SAH), a potent inhibitor of the methylation enzyme. COMT is also a key enzyme in the metabolism of catecholamines, such as dopamine and norepinephrine. Understanding an individual's genetic variation in these genes can provide valuable insights into their susceptibility to certain health conditions, including cardiovascular disease, mood disorders, and chronic fatigue. By offering a comprehensive assessment, this genetic testing can inform personalized nutritional and lifestyle interventions to support optimal methylation, thereby improving overall health and well-being. This non-invasive approach represents a significant step forward in personalized medicine.

Keywords**:** Genetic Methylation Testing, MTHFR, DNA Methylation, Genetic Polymorphism, Personalized Medicine

Acknowledgments: My deepest gratitude to all parties involved, family and colleagues for their continuous support, so that this research can be useful.

For citation:

Tamim, M. T. R., & Ahmed, R. (2025). Genetic Methylation Testing: Assessing Important Genes MTHFR, MTRR, MTR, AHCY, and COMT. *Radinka Journal of Health Science*, *3*(1), 428-434.

Introduction

Genetic methylation is a pivotal biochemical process that influences gene expression and cellular functions, thereby impacting overall health. This process, primarily involving the addition of methyl groups to DNA, is crucial for regulating various biological mechanisms, including development and disease susceptibility. Understanding methylation patterns can provide insights into individual genetic profiles and potential health risks, which is essential for personalized medicine. The following sections elaborate on the significance of DNA methylation in health and disease. DNA methylation typically occurs at cytosine bases near guanines (CpG sites) and is catalyzed by DNA methyltransferases (DNMTs) (Bommarito & Fry, 2019). It can repress gene expression, but its effects are context-dependent, influenced by chromatin structure and associated proteins (Hamidi et al., 2015). Aberrant DNA methylation patterns are linked to various diseases, including cancers and developmental disorders, highlighting its role in disease etiology (Robertson, 2005). Mutations in methylation machinery, such as DNMTs and TET proteins, have been implicated in disease phenotypes, emphasizing the importance of studying these alterations (Li et al., 2024). Recognizing individual methylation patterns can aid in identifying health risks and tailoring treatment regimens, thereby enhancing therapeutic efficacy (Dhar et al., 2021). Beyond the general principles of DNA methylation, a deeper understanding of its biological impact requires a look at the specific genes that drive this pathway.

The MTHFR, MTR, MTRR, AHCY, and COMT genes are essential for methylation processes, which influence important functions such as homocysteine metabolism, neurotransmitter balance, and detoxification. Mutations in these genes can disrupt these processes, increasing the risk of disease, particularly cardiovascular and neurological disorders. For example, MTHFR mutations, particularly the 677C>T and 1298A>C variants, are associated with elevated homocysteine levels, a known risk factor for cardiovascular disease and conditions such as hypertension and myocardial infarction (Afaque Alam, 2016; Coppedè et al., 2019). Similarly, variations in MTR and MTRR can exacerbate hyperhomocysteinemia, further increasing cardiovascular risk (Pokushalov et al., 2024; Beach et al., 2018), although B vitamin supplementation has been shown to help lower homocysteine levels in these cases. Additionally, genetic polymorphisms in these genes have also been linked to mental health problems, with certain alleles correlating with longer depressive episodes and cardiovascular comorbidities (Kasyanov et al., 2022; Levin & Varga, 2016), highlighting the profound link between one-carbon metabolism and overall health. To better understand these complex interactions, it is essential to examine the unique role of each gene, from MTHFR's central function in folate metabolism to COMT's impact on neurotransmitters.

The MTHFR gene is central to folate metabolism, playing a key role in converting homocysteine to methionine, a process vital for DNA repair and synthesis. Genetic variations, specifically the C677T and A1298C polymorphisms, can impair the MTHFR enzyme's function, leading to elevated homocysteine levels and an increased risk of health issues like cardiovascular disease and neural tube defects (Thomas & Fenech, 2008; Mazokopakis et al., 2023). These MTHFR mutations are also associated with various conditions, including certain types of cancer, depression, and osteoporosis (Cristalli et al., 2017; Du et al., 2018). Beyond MTHFR, other genes like MTR and MTRR are crucial for homocysteine remethylation, while AHCY helps maintain the methylation cycle by degrading a key byproduct (Zarembska et al., 2023 ; Wang et al., 2017). Finally, the COMT gene is important for breaking down neurotransmitters, with its variants potentially affecting psychiatric health outcomes (Shaikh et al., 2024; Coppedè et al., 2019). Comprehensive genetic methylation analysis of these five genes can provide valuable information regarding methylation efficiency and individual health risks. Detecting genetic variation in these pathways offers a higher level of personalized health, guiding interventions related to nutrition, lifestyle, and medical care. This article will discuss the significance of genetic methylation testing, emphasizing the roles of MTHFR, MTRR, MTR, AHCY, and COMT, and its implications for health and disease management.

Methodology

This study will use a comprehensive genetic methylation testing methodology to analyze key genes in the one-carbon cycle: MTHFR, MTRR, MTR, AHCY, and COMT. The objective is to assess genetic variations (polymorphisms) within these genes and correlate them with their potential impact on methylation efficiency and associated health risks.

Sample Collection and Preparation

Participants will be recruited based on specific inclusion criteria, and their consent will be obtained. Non-invasive buccal swabs will be used to collect DNA samples, ensuring minimal discomfort and ease of collection. After collection, the samples will be stored at an appropriate temperature to preserve DNA integrity and then transported to a certified laboratory for processing.

DNA Extraction and Analysis

Upon arrival, DNA will be extracted from the buccal swabs using a standardized protocol. The quality and concentration of the extracted DNA will be measured to ensure it meets the requirements for downstream analysis. Next, Polymerase Chain Reaction (PCR) will be performed to amplify the specific gene segments of interest (MTHFR, MTRR, MTR, AHCY, and COMT). Following amplification, genotyping will be carried out using advanced techniques such as Sanger sequencing or Real-Time PCR to identify specific single nucleotide polymorphisms (SNPs) within each gene.

Data Interpretation and Reporting

The raw genetic data will be analyzed by a bioinformatics team to identify the presence of key variants. The results will be interpreted in the context of scientific literature to determine the likely functional impact of each polymorphism on enzyme activity and the overall methylation process. A detailed report will be generated for each participant, outlining their specific genetic profile, explaining the role of each gene, and providing an assessment of their potential health risks related to methylation. The findings will be presented in a clear, accessible format to aid in understanding.

Ethical Considerations

All procedures will adhere to strict ethical guidelines, including participant confidentiality and data protection. The study protocol will be reviewed and approved by an institutional ethics committee before implementation. Participants will be fully informed about the purpose of the study and how their data will be used.

Results and Discussion

Genetic methylation testing, a targeted diagnostic tool, provides valuable insights into the efficiency of a person's methylation process by analyzing key genes such as MTHFR, MTRR, MTR, AHCY, and COMT. These test results reveal a clear picture of a person's unique genetic profile and how it may impact their health, allowing for a more personalized treatment approach. The clinical significance of this test is profound. Polymorphisms in MTHFR are strongly associated with high

homocysteine levels, a risk factor for cardiovascular disease, neurological disorders, and pregnancy complications. Similarly, variations in MTR and MTRR can interfere with vitamin B12 recycling and methionine synthesis, potentially leading to neurological symptoms, fatigue, and mood disorders. The AHCY gene's function in degrading methylation byproducts is crucial for preventing their buildup, which can hinder the overall process, while COMT variants can affect neurotransmitter balance, impacting mental health. Identifying these genetic markers allows clinicians to recommend tailored interventions, such as specific dietary changes, targeted vitamin supplementation, and lifestyle modifications, to reduce risk and improve patient outcomes.

While promising, genetic methylation testing has limitations. The main challenge lies in the complexity of the methylation cycle, which is not solely determined by genetics but also strongly influenced by environmental factors, diet, and lifestyle. Therefore, the presence of a genetic variant does not automatically mean a person will experience a health problem; rather, it indicates a predisposition. Overemphasizing genetic results without considering clinical symptoms and external factors can lead to misinterpretation and inappropriate interventions. Furthermore, current testing often focuses only on common polymorphisms, potentially missing other rare but significant variants. Accessibility and proper interpretation of results by healthcare professionals are also needed to avoid unnecessary concern.The future of genetic methylation testing lies in a more holistic and integrated approach. Combining genetic data with functional biomarkers such as homocysteine and folate levels will provide a more comprehensive picture of a person's methylation status. As technologies like Next-Generation Sequencing (NGS) become more accessible, testing will become more affordable and widespread. This will pave the way for a new era of truly personalized medicine, where treatment strategies are tailored based on an individual's unique genetic and epigenetic profile. Further research into gene-environment interactions and a greater focus on clinician education will be critical to fully realizing the potential of this valuable diagnostic tool.



Figure 1. Methylation pathway genes and their functions

1. MTHFR: This gene is responsible for converting folate into its active form, 5-MTHF. This is a crucial step for optimal folate metabolism, which in turn supports cardiovascular health. Conversely, mutations in this gene can lead to a buildup of homocysteine, a condition linked to various health problems.

2. MTRR: This gene works alongside MTHFR by recycling methylcobalamin (the active form of vitamin B12), an essential cofactor for the methylation process.
3. MTR: Utilizing methylcobalamin provided by MTRR, this gene converts homocysteine into methionine, a vital step for efficient methylation.
4. AHCY: This gene regulates the methylation cycle by breaking down SAH (S-adenosylhomocysteine), a byproduct that can inhibit methylation. This breakdown ensures the methylation cycle runs smoothly.
5. COMT: Responsible for metabolizing both dopamine and estrogen, this gene impacts emotional stability and overall health.

Conclusion

Genetic methylation analysis is a valuable diagnostic tool that assesses the efficiency of the body's methylation processes by examining key genes such as MTHFR, MTRR, MTR, AHCY, and COMT. These genes are crucial for regulating vital biological functions, including homocysteine metabolism, neurotransmitter balance, and detoxification. By identifying specific genetic variations, or polymorphisms, within these pathways, clinicians can better understand a patient's susceptibility to certain diseases and implement targeted health strategies. For example, mutations in MTHFR have been strongly linked to cardiovascular disease, while COMT polymorphisms can influence mood regulation and stress responses. This personalized genetic insight allows for tailored interventions like customized nutrition plans, supplementation with methylated B vitamins, and lifestyle modifications to enhance methylation efficacy and improve health outcomes.

Despite its clear potential, genetic methylation testing has notable challenges. Interpreting the results requires a sophisticated understanding of how genes interact with the environment, as the mere presence of a polymorphism doesn't always lead to functional impairment. Gene expression is significantly influenced by lifestyle, diet, and stress, emphasizing the need for an integrated approach to patient care that goes beyond a simple genetic report. Other hurdles include the high cost and limited accessibility of testing, as well as ethical concerns regarding data privacy. However, the future of this field is promising. Advancements in technology will lead to more precise and comprehensive testing, and a deeper understanding of gene-environment interactions will allow for more effective, personalized health plans. Ultimately, this will empower individuals to take proactive steps toward wellness and help clinicians provide more targeted and effective care.

Conflicts of Interest

The author declares that there is no conflict of interest.

References

Afaque Alam, M. (2016). Methylenetetrahydrofolate Reductase Gene Polymorphisms and Cardiovascular Diseases. *Cell & Developmental Biology*, *5*(2), 17-24. https://doi.org/10.4172/2168-9296.1000172

Beach, S. R. H., Lei, M. K., Simons, R. L., Dogan, M. V., Gibbons, F. X., & Philibert, R. A. (2018). *MTHFR* regulatory effects on methylation of CG05575921 in response to smoking: Effects are also discernable using *MTHFR* expression. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, *177*(5), 529–534. https://doi.org/10.1002/ajmg.b.32624

Bommarito, P. A., & Fry, R. C. (2019). The Role of DNA Methylation in Gene Regulation. In *Toxicoepigenetics* (pp. 127–151). Elsevier: Singapore https://doi.org/10.1016/B978-0-12-812433-8.00005-8

Coppedè, F., Stoccoro, A., Tannorella, P., Gallo, R., Nicolì, V., & Migliore, L. (2019). Association of Polymorphisms in Genes Involved in One-Carbon Metabolism with MTHFR Methylation Levels. *International Journal of Molecular Sciences*, *20*(15), 3754. https://doi.org/10.3390/ijms20153754

Cristalli, C. P., Zannini, C., Comai, G., Baraldi, O., Cuna, V., Cappuccilli, M., Mantovani, V., Natali, N., Cianciolo, G., & La Manna, G. (2017). Methylenetetrahydrofolate reductase, MTHFR, polymorphisms and predisposition to different multifactorial disorders. *Genes & Genomics*, *39*(7), 689–699. https://doi.org/10.1007/s13258-017-0552-5

Dhar, G. A., Saha, S., Mitra, P., & Nag Chaudhuri, R. (2021). DNA methylation and regulation of gene expression: Guardian of our health. *The Nucleus*, *64*(3), 259–270. https://doi.org/10.1007/s13237-021-00367-y

Du, B., Tian, H., Tian, D., Zhang, C., Wang, W., Wang, L., Ge, M., Hou, Q., & Zhang, W. (2018). Genetic polymorphisms of key enzymes in folate metabolism affect the efficacy of folate therapy in patients with hyperhomocysteinaemia. *British Journal of Nutrition*, *119*(8), 887–895. https://doi.org/10.1017/S0007114518000508

Hamidi, T., Singh, A. K., & Chen, T. (2015). Genetic Alterations of DNA Methylation Machinery in Human Diseases. *Epigenomics*, *7*(2), 247–265. https://doi.org/10.2217/epi.14.80

Kasyanov, E. D., Zhilyaeva, T. V., & Maso, G. E. (2022). Association of affective disorders and MTHFR, MTR, and MTRR gene polymorphisms: Preliminary results of a family study. *Neurology, Neuropsychiatry, Psychosomatics*, *14*(5), 13–21. https://doi.org/10.14412/2074-2711-2022-5-13-21

Levin, B. L., & Varga, E. (2016). MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature. *Journal of Genetic Counseling*, *25*(5), 901–911. https://doi.org/10.1007/s10897-016-9956-7

Li, L., Chen, R., Zhang, H., Li, J., Huang, H., Weng, J., Tan, H., Guo, T., Wang, M., & Xie, J. (2024). The epigenetic modification of DNA methylation in neurological diseases. *Frontiers in Immunology*, *15*, 1401962. https://doi.org/10.3389/fimmu.2024.1401962

Mazokopakis, E. E., Papadomanolaki, M. G., & Papadakis, J. A. (2023). Association of methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms with serum folate, cobalanin and homocysteine concentrations in Greek adults. *Scandinavian Journal of Clinical and Laboratory Investigation*, *83*(2), 69–73. https://doi.org/10.1080/00365513.2023.2167232

Pokushalov, E., Ponomarenko, A., Bayramova, S., Garcia, C., Pak, I., Shrainer, E., Ermolaeva, M., Kudlay, D., Johnson, M., & Miller, R. (2024). Effect of Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin (SolowaysTM) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial. *Nutrients*, *16*(11), 1550. https://doi.org/10.3390/nu16111550

Robertson, K. D. (2005). DNA methylation and human disease. *Nature Reviews Genetics*, *6*(8), 597–610. https://doi.org/10.1038/nrg1655

Shaikh, A. P., Makharadze, K., Nagervadze, M., Koridze, M., Khukhunaishvili, R., & Glonti, S. (2024). MTHFR C677T Gene Polymorphism and Association with Disorders. *WSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE*, *21*, 108–117. https://doi.org/10.37394/23208.2024.21.11

Thomas, P., & Fenech, M. (2008). Chapter 13 Methylenetetrahydrofolate Reductase, Common Polymorphisms, and Relation to Disease. In *Vitamins & Hormones* (Vol. 79, pp. 375–392). Elsevier. https://doi.org/10.1016/S0083-6729(08)00413-5

Wang, J., Ouyang, N., Qu, L., Lin, T., Zhang, X., Yu, Y., Jiang, C., Xie, L., Wang, L., Wang, Z., Ren, S., Chen, S., Huang, J., Liu, F., Huang, W., & Qin, X. (2017). Effect of MTHFR A1298C and MTRR A66G genetic mutations on homocysteine levels in the Chinese population: A systematic review and meta-analysis. *Journal of Translational Internal Medicine*, *5*(4), 220–229. https://doi.org/10.1515/jtim-2017-0037

Zarembska, E., Ślusarczyk, K., & Wrzosek, M. (2023). The Implication of a Polymorphism in the Methylenetetrahydrofolate Reductase Gene in Homocysteine Metabolism and Related Civilisation Diseases. *International Journal of Molecular Sciences*, *25*(1), 193. https://doi.org/10.3390/ijms25010193